BACKGROUND: Mutations of GDAP1 gene cause autosomal dominant and autosomal recessive Charcot-Marie-Tooth disease and more than 40 different mutations have been reported. The recessive Q163X mutation has been described in patients of Spanish ancestry, and a founder mutation in South American patients, originating in Spain has been demonstrated. OBJECTIVE: We describe physical and histological features, and the molecular impact of mutation Q163X in a Colombian family. METHODS: We report two female patients, daughters of consanguineous parents, with onset of symptoms within the first two years of life, developing severe functional impairment, without evidence of dysmorphic features, hoarseness or diaphragmatic paralysis. Electrophysiology tests showed a sensory and motor neuropathy with axonal pattern. Sequencing of GDAP1 gene was requested and the study identified a homozygous point mutation (c.487 C>T) in exon 4, resulting in a premature stop codon (p.Q163X). This result confirms the diagnosis of Charcot-Marie-Tooth disease, type 4A. RESULTS: The patients were referred to Physical Medicine and Rehabilitation service, in order to be evaluated for ambulation assistance. They have been followed by Pulmonology service, for pulmonary function assessment and diaphragmatic paralysis evaluation. Genetic counseling was offered. The study of the genealogy of the patient, phenotypic features, and electrophysiological findings must be included as valuable tools in the clinical approach of the patient with Charcot-Marie-Tooth disease, in order to define a causative mutation. In patients of South American origin, the presence of GDAP1 gene mutations should be considered, especially the Q163X mutation, as the cause of CMT4A disease.
BACKGROUND: Mutations ofGDAP1 gene cause autosomal dominant and autosomal recessive Charcot-Marie-Tooth disease and more than 40 different mutations have been reported. The recessive Q163X mutation has been described in patientsof Spanish ancestry, and a founder mutation in South American patients, originating in Spain has been demonstrated. OBJECTIVE: We describe physical and histological features, and the molecular impact of mutation Q163X in a Colombian family. METHODS: We report two female patients, daughters of consanguineous parents, with onset of symptoms within the first two years of life, developing severe functional impairment, without evidence ofdysmorphic features, hoarseness or diaphragmatic paralysis. Electrophysiology tests showed a sensory and motor neuropathy with axonal pattern. Sequencing ofGDAP1 gene was requested and the study identified a homozygous point mutation (c.487 C>T) in exon 4, resulting in a premature stop codon (p.Q163X). This result confirms the diagnosis ofCharcot-Marie-Tooth disease, type 4A. RESULTS: The patients were referred to Physical Medicine and Rehabilitation service, in order to be evaluated for ambulation assistance. They have been followed by Pulmonology service, for pulmonary function assessment and diaphragmatic paralysis evaluation. Genetic counseling was offered. The study of the genealogy of the patient, phenotypic features, and electrophysiological findings must be included as valuable tools in the clinical approach of the patient with Charcot-Marie-Tooth disease, in order to define a causative mutation. In patientsof South American origin, the presence ofGDAP1 gene mutations should be considered, especially the Q163X mutation, as the cause ofCMT4A disease.
Entities:
Keywords:
Charcot-Marie-Tooth Disease; Founder effect; axonal neuropathy; genetic counseling; hereditary sensory and motor neuropathy
Authors: R Claramunt; L Pedrola; T Sevilla; A López de Munain; J Berciano; A Cuesta; B Sánchez-Navarro; J M Millán; G M Saifi; J R Lupski; J J Vílchez; C Espinós; F Palau Journal: J Med Genet Date: 2005-04 Impact factor: 6.318
Authors: Ana Cuesta; Laia Pedrola; Teresa Sevilla; Javier García-Planells; María José Chumillas; Fernando Mayordomo; Eric LeGuern; Ignacio Marín; Juan J Vílchez; Francesc Palau Journal: Nat Genet Date: 2001-12-17 Impact factor: 38.330
Authors: J D England; G S Gronseth; G Franklin; G T Carter; L J Kinsella; J A Cohen; A K Asbury; K Szigeti; J R Lupski; N Latov; R A Lewis; P A Low; M A Fisher; D N Herrmann; J F Howard; G Lauria; R G Miller; M Polydefkis; A J Sumner Journal: Neurology Date: 2008-12-03 Impact factor: 9.910
Authors: Isabel Banchs; Carlos Casasnovas; Antonia Albertí; Laura De Jorge; Mónica Povedano; Jordi Montero; Juan Antonio Martínez-Matos; Victor Volpini Journal: J Biomed Biotechnol Date: 2009-10-08
Authors: Teresa Sevilla; Ana Cuesta; María José Chumillas; Fernando Mayordomo; Laia Pedrola; Francesc Palau; Juan J Vílchez Journal: Brain Date: 2003-06-23 Impact factor: 13.501
Authors: Matthew R Googins; Aigbirhemwen O Woghiren-Afegbua; Michael Calderon; Claudette M St Croix; Kirill I Kiselyov; Andrew P VanDemark Journal: FASEB J Date: 2020-04-10 Impact factor: 5.834